Genetic risk factors for hepatotoxicity during anti tuberculosis treatment.

Genetic risk factors for hepatotoxicity during anti tuberculosis treatment. - HEPTB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29714

Enrollment

325

Registered

2006-08-11

Start date

2006-07-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leverbijwerkingen van standaard tuberculosebehandeling hepatotoxicity liver side effects

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patient is treated for tuberculosis (pulmonary or extra-pulmonary) with standard treatment containing at least isoniazid, rifampicin and pyrazinamide. - Age: above 18 years.

Exclusion criteria

Exclusion criteria: - Patient receives treatment for multi-drug resistant tuberculosis. - Patient also receives antiretroviral treatment and developed liver function disorders immediately after the start of ART.

Design outcomes

Primary

Measure	Time frame
Association between ATDH and genetic polymorphisms (single nucleotide polymorphisms) in drug metabolising enzymes and regulators of enzyme expression. Enzymes: N-acetyltransferase 2, glutathione S-transferase, cytochrome P450 2E1. Receptors: pregnane X-receptor (PXR), multidrug resistance gene 1 (MDR1).	—

Secondary

Measure	Time frame
Association between ATDH and other risk factors, including age, sex, weight and length, underlying liver disease and HIV-status.	—

Countries

Netherlands

Outcome results